CHINA PHARMA HOLDINGS, INC. Financing Receivable, Allowance for Credit Loss, Current
CHINA PHARMA HOLDINGS, INC. (CPHI) had Financing Receivable, Allowance for Credit Loss, Current of $35.08 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts and Financing Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForNotesAndLoansReceivableCurrent · last filed 2026-08-14
- 2026-06-30: Financing Receivable, Allowance for Credit Loss, Current $35.08K.
- 2025-12-31: Financing Receivable, Allowance for Credit Loss, Current $32.15K.
| Period end | Financing Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $35.08K 10-Q · filed 2026-08-14 |
| 2025-12-31 | $32.15K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |